Antibody against acetylcholine receptor induces an increase in the rate of degradation of acetylcholine receptors on a mouse cell line (BC3H-1) and cultured rat skeletal muscle. The increased rate of degradation results in a lowered density of acetylcholine receptors on muscle membrane and a lowered sensitivity to iontophoretically applied acetylcholine. The modulation of acetylcholine receptor is energy, temperature, and time dependent and may be related to antigenic modulation found in other systems. Acetylcholine noise analysis demonstrates that antibody against acetylcholine receptor reduces the channel mean conductance and mean open time slightly.
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It is concluded that antibody binds to the acetylcholine receptor, impairs its function, and induces receptor degradation. This results in a lowered density of acetylcholine receptor and a lowered sensitivity to acetylcholine. Patients with myasthenia gravis have antibodies to their acetylcholine receptor in their serum. Antigenic modulation of receptor in the muscle of patients with myasthenia gravis could contribute to the observed decrease in amplitudes of miniature endplate potentials and in muscle acetylcholine sensitivity, and the symptoms of muscular weakness.
The regulation of the density and distribution of the acetylcholine (ACh) receptors found on skeletal muscle has been of great interest to biologists because it may reflect a fundamental process important in synaptogenesis (1, 2) . In this paper we describe a form of regulation that occurs when muscle is exposed to antibodies directed against purified ACh receptor. Our experiments show that antibody against receptor induces an increase in the rate of degradation of ACh receptors and a lowered sensitivity to iontophoretically applied ACh. Our previous work has shown that skeletal muscle from rats immunized against purified ACh receptor (torpedo or electric eel) has a reduced sensitivity to ACh (3) , exhibits reduced miniature endplate potential amplitudes (3, 4) , and contains decreased amounts of receptor (5) . In immunized rats, antibody against rat receptor is found both in the serum (6) and bound to muscle ACh receptors (5) . Serum taken from such immunized rats and applied to muscle in vitro reduces the sensitivity of the muscle to ACh (3) .
Human patients with myasthenia gravis also have antibodies against the ACh receptor in their sera (6) (7) (8) (9) (10) and bound to their muscle ACh receptors (J. Lindstrom and E. Lambert, unpublished data). Furthermore, their muscles exhibit reduced miniature endplate potential amplitudes and a reduced sensitivity to ACh (11) (12) (13) and contain decreased amounts of receptor (ref 14 ; Lindstrom and Lambert, unpublished data).
The following experiments were performed to determine the mechanism by which antibody against the ACh receptor reduces muscle sensitivity to ACh.
MATERIALS AND METHODS
Cell Culture. The clonal mouse muscle cell line BC3H-1 (15, 16) was grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (FCS). The cells were allowed to reach the stationary phase and were used for experiments within 10 days.
Rat primary skeletal muscle cultures were prepared from 17-to 20-day Lewis rat embryos. Limb muscle was dissected from skin, bone, and connective tissue and minced into small pieces (1 mm3). The tissue was dissociated enzymatically as described elsewhere (17) (6) . The sera from 160 immunized animals were pooled and used as antiserum against ACh receptor. The pooled serum was titered for antibody against rat ACh receptor by immunoprecipitation as described (6) . It Table 2 foi further details.
Preparation of 125I-Labeled a-Bungarotoxin ("251-a-BuTx).
a-BuTx was purified from the venom of the krait Bungarus multicinctus, Ross Allen Serpentarium. The a-BuTx was iodinated by the iodine monochloride method (18) . Abbreviations: 125I-a-BuTx, 125I-labeled a-bungarotoxin; Dnp, 2,4-dinitrophenol; FCS, fetal calf serum; ACh, acetylcholine; prep medium, Dulbecco's modified Eagle's medium in which the bicarbonate is replaced with 1.08 mM Na2PO4/1.5 mM KH2PO4. a-BuTx was purified by chromatography (16) and used in these experiments. The ability of muscle cells to bind 125I-a-BuTx was measured by an assay described elsewhere (19) .
RESULTS
A model system utilizing muscles grown in tissue culture was used to study the effect of antibodies against receptor on ACh receptor density and function. Two sources of muscle were used (i) a clonal cell line BC3H-1, which has a high density of nicotinic ACh receptors in its membrane (15, 16) , and (ii) primary skeletal muscle cultures from rat (Lewis) limbs. Antisera against ACh receptor were obtained from rats (Lewis) immunized with purified eel ACh receptor (4) (5) (6) .
The ACh receptor density and degradation rate were determined by measuring the muscle membrane's ability to bind and then degrade bound 125I-a-BuTx. a-BuTx is a protein (molecular weight 8000) isolated from the venom of the krait that binds specifically and with high affinity to the ACh receptor (20) . The degradation of bound 125I-a-BuTx is an accurate measure of the turnover of ACh receptor (21, 22) . Receptor function was assayed by the iontophoretic application of ACh to the muscle surface, and the properties of individual ACh receptor channels were determined by means of ACh noise analysis (23, 24) . Effect of Antisera against ACh Receptor on the Number of a-BuTx Binding Sites. The ability of both BC3H-1 and primary rat muscle cells to bind 1251-a-BuTx is reduced by incubation at 370 for 2-3 hr in medium containing antiserum against ACh receptor (Table 1) . Serum from rats immunized only with adjuvant had no effect when compared to controls that were incubated in fetal calf serum ( Table 1) .
The antibody-induced loss of a-BuTx binding capacity is blocked by a mixture of 2,4-dinitrophenol (Dnp) plus NaF and is much reduced at 21-23° (Table 1) . These experiments show that the loss of a-BuTx binding capacity is not the result of the simple binding of antibody to the receptor. It must reflect some process that requires energy. A direct immunoprecipitation assay was used to determine the rate of binding of antibody against ACh receptor to surface ACh receptor. After a 30-min incubation, about 70% of the surface ACh receptors had antibody bound to them. After 60 min, about 86% of the surface ACh receptors had antibody bound to them. The rate of antibody binding was not significantly effected by temperature (21-23°or 37°).
Loss of 1251-a-BuTx from Muscle Cells Treated with Antiserum against ACh. Receptor. The reduced binding of aBuTx after incubation with antiserum against ACh receptor (Table 1) can be explained by an increased rate of degradation of membrane ACh receptor. This was demonstrated by measuring the rate of loss of bound toxin in the presence of antiserum against ACh receptor. 125I-a-BuTx was bound to the muscle (BC3H-1) cells in culture and excess a-BuTx was washed away. The rate of 125I release into the medium from the muscle was measured in the presence of antiserum against ACh receptor. This experiment demonstrated that antiserum against ACh receptor stimulates the release of 125I into the medium (Fig. 1A) . Under control conditions (12% FCS or serum from rats immunized with adjuvant) the 125I was released at a rate of 12% per hr (Fig. 1A) . This agrees well with values previously reported for the rate of (25) and the BC3H-1 cell line (16) . In the presence of antibody against the ACh receptor, the rate of 125I release is increased to 70% per hr (Fig. WA) . Similar results were obtained when purified gamma globulin was used, demonstrating that complement is not involved in this reaction (Fig. 2 B and C) .
In the presence of blockers of energy metabolism (5 mM Dnp plus 2 mM NaF) there is no stimulation of 125I release by antiserum against ACh receptor (Fig. 1B) . The antibody-stimulated release of 125I cannot therefore be due to the simple dissociation of the 125I-a-BuTx-receptor complex. This is comfirmed by the finding that most of the 125I in the culture medium is no longer associated with intact a-BuTx. Media from 125I-a-BuTx-labeled muscle cultures that had been incubated in the presence of purified antibody were fractionated on BioGel P2 columns (Fig.  2) . This experiment demonstrates that most of the 125I released into the medium is recovered in the included volume of the P2 column, the position of low-molecular-weight material (Fig.  2 B and C) . Furthermore, the increased release of 125I seen in the presence of antibody against receptor (Fig. 1A) is due to an increase in the release of small-molecular-weight 125I-labeled material, presumably 125I-labeled tyrosine (Fig. 2C) . There is no increase in the release of intact 125I-a-BuTx, as would be the case if the antibody against ACh receptor simply increased the rate of dissociation of the a-BuTx-ACh receptor complex. When 125I-a-BuTx is incubated with antiserum against ACh receptor and with muscle cells in the presence of an antagonist of the ACh receptor (10-3 M d-tubocurarine) no degradation of 125I-a-BuTx is observed (Fig. 2A) . This demonstrates that there is no substance in antiserum against ACh receptor, or material produced and secreted by muscle, that degrades 125I-a-BuTx. Thus, 125I-a-BuTx must be bound to the ACh receptor to be degraded. This finding supports the simplest interpretation that 1251 release is a measure of the degradation of the 125I-a-BuTx-receptor complex (25, 26) . This is confirmed by recent experiments showing that the rate of ACh receptor turnover inferred from 125I release is the same as that obtained by direct measurement of ACh receptor turnover (21, 22) .
The slow release of 125I from cells poisoned by Dnp/NaF is probably due to the simple dissociation of the 125I-a-BuTx-ACh receptor complex since the released 1251 runs in the void volume, the position of native 125I-a-BuTx (Fig. 2D) .
At 23' the rate of 125I-a-BuTx degradation is much reduced, and there is no stimulation of degradation by antiserum against ACh receptor (Fig. 2 E and F ACh-induced membrane current fluctuations were recorded from cultured muscle cells obtained from Lewis rat embryonic skeletal tissue. Cells were rounded up by exposing them to colchicine (10-7 M) for 1-2 days before recording. Suitable cells had input resistances of 5-20 Mg (at 80 mV) and were 50-100 um in diameter. Cells were voltage clamped using two intracellular electrodes filled with potassium acetate (resistances of 5-15 MR). Feedback gains were 900-1200. Clamping currents were measured by a virtual ground current monitor. ACh was applied iontophoretically from a micropipette positioned 25-50 /im from the cell. All recordings were done at 230 in medium containing 150 mM NaCl/5 mM KCl/1.8 mM CaCl2/5 mM N-2-hydroxyethylpiperazine-N'-ethanesulfonic acid-NaOH, pH 7.4. Methods of spectral analysis were similar to those reported elsewhere (23) . Data were recorded on analogue tape and the Fast Fourier Transform was performed on bandpass filtered records (0.3-250 Hz, 24 dB/octave rolloff) of 1.96 sec length containing 2048 digitized samples. Typically, eight to ten records of ACh-induced noise and five to six records of control noise were used to compute each power spectrum. The spectra were fitted using a least squares method by a function of the form:
where f = frequency, X = mean channel open time, v = channel conductance, A = mean current, and V = the clamped membrane potential (reversal potential being 0 mV). Numbers in parentheses are the number of muscle cells examined.
*At-60mV. treated with antibody against ACh receptor was 15% less than that of adjuvant-treated cells (P < 0.01, Mann-Whitney nonparametric test), and the mean channel open time was 23% less (P < 0.05). These small differences may represent impeded channel function due to bound antibody. The mean charge passed through a channel during a single opening in the presence of antibody against receptor was 1.1 X 10-14 + 0.2 X 10-14 coulomb. This was about % the mean charge passed by a single channel in adjuvant serum, 1.6 X 10-14 0.4 X 10-14 coulomb (P < 0.001).
The conductance and mean open time were reduced slightly. We conclude that the decreased ACh sensitivity is due to two processes: (i) a small decrease in ACh receptor function due to binding of antibody and (ii) a decrease in ACh receptor density due to an antibody-induced degradation of ACh receptor.
Recently we have analyzed the effect of sera from human myasthenia gravis patients on cultured human muscle. Our results show that human muscles exposed to sera from myasthenia gravis patients have reduced muscle sensitivity to ACh. The reduction in sensitivity is temperature dependent and may involve a reduction in receptor density. In addition, sera from myasthenia gravis patients increase the rate of ACh receptor degradation in the BC&H-1 muscle cell line (Bevan, Kullberg, and Heinemann, unpublished data).
We have studied the effect of antisera against ACh receptor on the ACh receptor found on cultured muscle. Our finding that the density of ACh receptors is reduced cannot, at present, be extended to the adult neuromuscular junction. The ACh receptor found on cultured muscle is presumably analogous to the extrajunctional receptor found on denervated skeletal muscle. The receptors found at endplates are more stable (25, 27) and have several different properties that could affect their response to antibody (28-S0). -With these reservations, however, it is clear that an antibody-induced modulation of ACh receptor leading to a lowered density could contribute to the changes that occur in muscle in immunized rats as well as in human myasthenia gravis patients. Reduced miniature endplate potential amplitudes and reduced muscle sensitivity to ACh would all be consequences of receptor modulation. Rats immunized against ACh receptor have reduced numbers of ACh receptors (5) . Muscle from human myasthenia gravis patients also are deficient in ACh receptor (ref 14; Lindstrom and Lambert, unpublished data). Whether or not this observed deficiency in receptor density found in vivo is due to modulation is under investigation.
The finding that antibody against the ACh receptor induces a reduction in the density of ACh receptors is similar to the phenomenon of antigenic modulation found in other systems, for example H-2 antigen, TL antigen, and surface immunoglobulins (31) (32) (33) . The densities of hormone receptors [insulin (34) , thyrotropin-releasing hormone (35) ] and the fl-adrenergic neurotransmitter receptor (36, 37) are modulated by specific receptor ligands. It seems plausible to us that, in addition to antibody, other ligands will be found that regulate the density of ACh receptor on muscle.
